Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Bekjempelse av Alzheimers gjennom søvn og trening (CASE)

23. oktober 2026 oppdatert av: Azizi Seixas, University of Miami

Bekjempelse av Alzheimers gjennom søvn og trening (CASE)

The Combating Alzheimer's through Sleep and Exercise (CASE) study is an exploratory, hypothesis-generating trial designed to: (1) assess whether improvements in sleep are associated with improvements in cognitive performance and cardiovascular and metabolic health; (2) evaluate the effects of structured, moderate-level aerobic and anaerobic exercise on cognitive performance and cardiovascular and metabolic health; (3) examine the combined, potentially synergistic effects of both interventions on cognitive performance and cardiovascular and metabolic health; and (4) investigate the role of light exposure as a potential modulator of sleep parameters.

Studieoversikt

Studietype

Intervensjonell

Registrering (Antatt)

60

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studer Kontakt Backup

Studiesteder

    • Florida
      • Miami, Florida, Forente stater, 33136
        • Rekruttering
        • University of Miami Hospitals
        • Ta kontakt med:
        • Hovedetterforsker:
          • Azizi A Seixas, PhD
        • Underetterforsker:
          • Alberto Ramos, MD
        • Ta kontakt med:
        • Underetterforsker:
          • Debbie Chung, PhD

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

55 år til 80 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Ja

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  1. Aged 55-80 years at the time of the screening visit
  2. Able to ambulate safely and independently
  3. Able to safely perform moderate-intensity exercise as per the Physical Activity Readiness Questionnaire (PAR-Q, a validated exercise readiness questionnaire)
  4. Able to wear and use Fitbit wristwatch and/or the Elemind Neuromodulation headband and Lys devices
  5. Able to operate a digital device like mobile phone or computer
  6. Able and willing to provide venous blood samples
  7. Able to understand and speak English (our AR-based MCI diagnosis tool does not yet have capacity for other languages)
  8. Able to self-report a history of cognitive changes or impairment
  9. Be cognitively able (including those with and without MCI) and willing to provide informed consent
  10. Body weight <400 pounds (<181.4kg) in order to safely operate the NuStep T4r Recumbent Stepper stationary bicycle

Exclusion Criteria:

  1. Severe mobility limitations that prevent safe participation in moderate exercise protocols
  2. Unstable or uncontrolled medical conditions (e.g., recent cardiovascular event (<6 months), cerebrovascular accident or transient ischemic attack (<6 months), active cancer, or uncontrolled diabetes) that pose safety concerns
  3. Inability to complete intake screening procedures
  4. Severe uncorrected hearing impairment-particularly if it precludes effective utilization of the Elemind Neuromodulation headband-and/or vision impairment that interferes with digital device usage or in-person exercise guidance
  5. Determined to have Alzheimer's/dementia based on performance on the Quick Mild Cognitive Impairment (QMCI).
  6. Inability or unwillingness to learn or engage with digital devices (e.g., smartphone, Fitbit, Elemind, or Lys), even with staff support
  7. Regular pre-study engagement in ≥150 minutes of moderate-level and/or ≥75 minutes of vigorous-level exercise per week based on Fitbit data obtained during the initial seven-day onboarding screening period
  8. Determined to have sufficient sleep, as defined by a sleep efficiency mean of ≥80%) based on Elemind Neuromodulation headband data obtained during the initial seven-day onboarding screening period
  9. Current usage of disease-modifying therapy targeting amyloid (e.g., anti-amyloid monoclonal antibodies) or tau
  10. Body weight ≥400 pounds (≥181.4kg), which would pose a safety risk during the operation of the NuStep recumbent stationary bicycle

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Forebygging
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Sleep Only Group

Participants in this group will wear the Elemind headband 3-4 times weekly for 8 weeks.

The Elemind Neuromodulation headband is a wearable device that utilizes noninvasive, electroencephalography-based (EEG-based) technology to induce a sleep state more rapidly via personalized acoustic stimulation. Specifically, the headband uses a closed-loop system, meaning that the headband conveys stimulation based upon recorded neural activity in order to modulate real-time oscillating circuits at the macroscopic level. This device uses five dry, flexible EEG electrodes-including three recording electrodes that are positioned at the Fpz and Fp1/2 electrode sites in accordance with the 10-20 International System of electrode placement and two silicone rubber-based, linked reference electrodes located at the mastoids-to measure neural activity during sleep and provide an estimation of the phases of real-time neural oscillations. The headband generates a sound pulse by identifying alpha neural oscillations in real-time through endpoint-corrected Hilbert Transform algorithm.

Aktiv komparator: Exercise Only Group

Participants in this group will participate in a structured, on-site, twice a week exercise program for 60 minutes/session for 8 weeks (16 total sessions). Each exercise session is comprised of 60 minutes, including 10 minutes of warm-up, 20 minutes of cardiovascular exercise on a stationary bike, 20 minutes of resistance training (1 day of upper body focus, 1 day of lower body focus each week), and 10 minutes of cooling off).

Participants randomized to the exercise-only group will engage in an 8-week, home- and site-based exercise intervention designed for older adults across a range of cognitive and physical function levels. All site-based sessions will occur in-person at the study facility under supervision of trained staff. Each week, participants will attend two 60-minute structured exercise sessions, consisting of aerobic training and resistance training. On the remaining five days when subjects will not engage in structured exercise, subjects will be asked to engage in 30 minutes of moderate-intensity walking activities. In-lab exercise protocols will be fully standardized to ensure consistency of exercise dosage and fidelity across participants. The target exercise load will be 270 minutes of moderate-intensity exercise weekly for 8 weeks.

Aktiv komparator: Exercise and Sleep Group

Participants in this group will take part in the on-site, structured exercise program twice per week for 8 weeks in additional to wearing the Elemind headband 3-4 times per week for 8 weeks.

The Elemind Neuromodulation headband is a wearable device that utilizes noninvasive, electroencephalography-based (EEG-based) technology to induce a sleep state more rapidly via personalized acoustic stimulation. Specifically, the headband uses a closed-loop system, meaning that the headband conveys stimulation based upon recorded neural activity in order to modulate real-time oscillating circuits at the macroscopic level. This device uses five dry, flexible EEG electrodes-including three recording electrodes that are positioned at the Fpz and Fp1/2 electrode sites in accordance with the 10-20 International System of electrode placement and two silicone rubber-based, linked reference electrodes located at the mastoids-to measure neural activity during sleep and provide an estimation of the phases of real-time neural oscillations. The headband generates a sound pulse by identifying alpha neural oscillations in real-time through endpoint-corrected Hilbert Transform algorithm.

Participants randomized to the exercise-only group will engage in an 8-week, home- and site-based exercise intervention designed for older adults across a range of cognitive and physical function levels. All site-based sessions will occur in-person at the study facility under supervision of trained staff. Each week, participants will attend two 60-minute structured exercise sessions, consisting of aerobic training and resistance training. On the remaining five days when subjects will not engage in structured exercise, subjects will be asked to engage in 30 minutes of moderate-intensity walking activities. In-lab exercise protocols will be fully standardized to ensure consistency of exercise dosage and fidelity across participants. The target exercise load will be 270 minutes of moderate-intensity exercise weekly for 8 weeks.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Glycated Hemoglobin (HbA1c) Levels
Tidsramme: Up to Week 8

Measured from blood sample

Up to Week 8
Total Cholesterol Levels
Tidsramme: Up to Week 8

Measured from blood sample

Up to Week 8
Triglycerides Levels
Tidsramme: Up to Week 8

Measured from blood sample

Up to Week 8
High-sensitivity C-reactive protein (hs-CRP) Levels
Tidsramme: Up to Week 8

Measured from blood sample

Up to Week 8
Low-Density Lipoprotein (LDL) Levels
Tidsramme: Up to Week 8

Measured from blood sample

Up to Week 8
C-Peptides
Tidsramme: Up to Week 8

Measured from blood sample

Up to Week 8
High-Density Lipoprotein (HDL) Levels
Tidsramme: Up to Week 8

Measured from blood sample

Up to Week 8
Cognitive Function
Tidsramme: Up to 8 weeks

Cognitive function gauged from Altoida's Digital Neuro-Signatures

Up to 8 weeks
Insulin Levels
Tidsramme: Up to 8 weeks

Measured from blood sample

Up to 8 weeks
Neurofilament light chain
Tidsramme: Up to Week 8

Measured from blood sample

Up to Week 8

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Total Sleep Duration
Tidsramme: Up to Week 8

Measured from Elemind

Up to Week 8
Slow Wave Sleep Duration
Tidsramme: Up to Week 8

Measured from Elemind

Up to Week 8
%Slow-wave Sleep
Tidsramme: Up to Week 8

Measured by Elemind headband

Up to Week 8
Rapid Eye Movement Duration
Tidsramme: Up to Week 8

Measured by Elemind headband

Up to Week 8
%REM
Tidsramme: Up to Week 8

Measured by Elemind headband

Up to Week 8
Light Non-Rapid Eye Movement Duration
Tidsramme: Up to Week 8

Measured by Elemind headband

Up to Week 8
%Light Non-Rapid Eye Movement Sleep
Tidsramme: Up to Week 8

Measured by Elemind headband

Up to Week 8
Sleep Efficiency
Tidsramme: Up to Week 8

Measured by Elemind headband

Up to Week 8
Sleep Onset Latency
Tidsramme: Up to Week 8

Measured by Elemind headband

Up to Week 8
Restlessness (Restless Bouts/Hour during Sleep)
Tidsramme: Up to Week 8

Measured by Elemind headband

Up to Week 8

Andre resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Light Exposure
Tidsramme: Up to Week 8

Measured by LYS Device

Up to Week 8
Psychosocial Metrics
Tidsramme: Up to Week 8

Measured by Questionnaires

Up to Week 8

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Hovedetterforsker: Azizi A Seixas, PhD, University of Miami

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

1. mars 2023

Primær fullføring (Antatt)

30. desember 2028

Studiet fullført (Antatt)

30. desember 2028

Datoer for studieregistrering

Først innsendt

19. april 2021

Først innsendt som oppfylte QC-kriteriene

19. april 2021

Først lagt ut (Faktiske)

22. april 2021

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

27. oktober 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

23. oktober 2026

Sist bekreftet

1. oktober 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

produkt produsert i og eksportert fra USA

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere